Title page for etd-0716113-111414


[Back to Results | New Search]

URN etd-0716113-111414
Author Jhuan-Yi Liou
Author's Email Address No Public.
Statistics This thesis had been viewed 5581 times. Download 75 times.
Department Institute of Biomedical Sciences
Year 2012
Semester 2
Degree Master
Type of Document
Language English
Title 2-Deoxyglucose Enhances the Chemosensitivity of B16-F10 Melanoma Cells to Cisplatin
Date of Defense 2013-07-18
Page Count 57
Keyword
  • giant cells
  • energy
  • chemoresistance
  • Melanoma
  • 2-DG
  • cisplatin
  • Abstract Although cisplatin is among the most potent antitumor agents, cisplatin-based chemotherapy has shown limited effectiveness for treating melanoma. Our previous work showed that cisplatin induces chemoresistance in melanoma by elevating cancer stemness marker ABCB5, which indicates the involvement of chemoresistance mechanisms in the ATP synthesis pathway. Specifically, cisplatin treatment increases production of mitochondria and ATP in melanoma. The glucose analog 2-deoxyglucose (2-DG), which is a glycolytic inhibitor, decreases cellular ATP. Specifically, 2-DG attenuates the elevation of cellular ATP caused by cisplatin in B16-F10 melanoma cells. After cisplatin treatment, 2-DG also reduces cellular levels of ABCB5. Moreover, 2-DG enhances the inhibitory effect of cisplatin on anchorage-independent growth of B16-F10 melanoma cells. Invasion assays further show that a combined treatment with 2-DG (2 mM) and cisplatin (3 μM) has a larger attenuating effect on the invasiveness of B16-F10 melanoma cells compared to 2-DG alone or cisplatin alone. In conclusion, treatment combining the glycolytic inhibitor 2-DG with cisplatin may have potent applications in melanoma therapy.
    Advisory Committee
  • Kuang-hung Cheng - chair
  • Wang Hui-Min - co-chair
  • Ming-Hong Tai - advisor
  • Files
  • etd-0716113-111414.pdf
  • Indicate in-campus at 0 year and off-campus access at 5 year.
    Date of Submission 2013-08-16

    [Back to Results | New Search]


    Browse | Search All Available ETDs

    If you have more questions or technical problems, please contact eThesys